Does Brodalumab Interact with Cyclosporine?
CDI records a moderate classification for Brodalumab and Cyclosporine. The stored summary is: SILIQ may modulate serum levels of cytokines affecting CYP450 enzyme formation, potentially altering cyclosporine metabolism. Monitor drug concentration and consider dosage modification upon initiation or discontinuation of SILIQ. The mechanism involves altered cyp450 enzyme formation due to modulation of cytokine levels. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Brodalumab Class
- Interleukin-17 Receptor A Antagonist
- Cyclosporine Class
- Calcineurin Inhibitor Immunosuppressant
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Altered CYP450 enzyme formation due to modulation of cytokine levels
What To Tell Your Doctor or Pharmacist
If you are taking Brodalumab and your doctor is considering prescribing Cyclosporine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider